Anti-VEGF Ophthalmic Drug Market
Anti-VEGF Ophthalmic Drug Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Anti-VEGF Ophthalmic Drug Market Size and Growth
The Anti-VEGF ophthalmic drug market is experiencing robust growth, driven by increasing prevalence of eye disorders and technological advancements. The market size was valued at approximately $9 billion in 2023 and is projected to expand significantly due to rising demand for effective treatment options and ongoing research in innovative therapies.
Companies Covered
(Covid 19 Impact Covered)
◍ Eyetech
◍ Pfizer Inc
◍ Roche
◍ Novartis
◍ Regeneron
◍ Bayer
◍ Regeneron Pharmaceuticals
◍ Genentech
◍ Samsung Bioepis
◍ Biogen
◍ Qilu Pharmaceutical
◍ Innovent Biologics
◍ Kanghong Pharmaceutical
◍ Taikang Biology
The Anti-VEGF ophthalmic drug market is competitive with key players like Regeneron, Novartis, Roche, and Bayer leading through innovative products like Eylea and Lucentis. These companies drive market growth via R&D, strategic partnerships, and expanding indications. Sales figures include:
- Regeneron: $5.8 billion (2022)
- Novartis: $5.5 billion (2022) Request Sample Report
Market Segmentation
By Application
Online Sales
Hospital
Clinic
Retail Pharmacy
Others
Request Sample Report
By Product
Pegaptanib
Ranibizumab
Aflibercept
Brolucizumab
Faricimab
Market Growth
Request Sample Report
$ X Billion USD
